Unknown OBSERVATIONAL NCT05862181

The Comparison Between HepaSphere Drug-eluting Bead Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy in Advanced Hepatocellular Carcinoma

Efficacy and Safety of HepaSphere Drug-eluting Bead Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy in Advanced Hepatocellular Carcinoma

Sponsor: Peking University Cancer Hospital & Institute

Conditions Advanced Hepatocellular Carcinoma (HCC)

Interventions DEB-TACE plus HAIC or HAIC alone

Updated 4 times since 2023 Last updated: May 19, 2023 Started: Jan 1, 2023 Primary completion: Jul 31, 2023 Completion: Dec 31, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Advanced Hepatocellular Carcinoma (HCC), this trial is ongoing. The trial is conducted by Peking University Cancer Hospital & Institute and has accumulated 4 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

4 versions recorded

Apr 2025 — Present [monthly]

Unknown

Status: Recruiting → Unknown
Sep 2024 — Apr 2025 [monthly]

Recruiting
Jul 2024 — Sep 2024 [monthly]

Recruiting
Jun 2023 — Jul 2024 [monthly]

Recruiting

First recorded

Jan 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Peking University Cancer Hospital & Institute

Data source: Peking University Cancer Hospital & Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China